Year : 2012
Number of Pages : 65
leaves
Adviser : Dr. Roger D.
Posadas
Executive Summary
The
pharmaceutical industry is large, high-growth, globalized and innovation
intensive. Its products are directed to satisfy customer needs in an
area-health care-whose importance for the society is fundamental and rapidly
increasing. Health care and therapeutics are among the most relevant issues in
the definition of the concepts of welfare and democracy in the new century.
Indeed, over the last two decades, the world pharmaceutical industry has
undergone profound transformations. It has been experiencing a series of
technological and institutional shocks that have affected all the stages of the
value chain and have led to deep changes in firms' organization and in market
structure, within domestic markets, regionally and globally. In 2010, the
Philippine pharmaceutical and healthcare industry is valued at over US 3.0
billion dollars. In the 2011 Business Environment Ratings published by Business
Monitor International (BMI), the Philippines ranks 11th of the 17 regional
markets surveyed in the Asia Pacific region, below Thailand and above
Indonesia. The Philippines' pharmaceutical rating is 49.2, which is well below
the average of 52.5 for the region. However, there is evidence that the market
is maturing, with calls to expand the socialized healthcare system to serve the
entire nation (BMI, 2011). As an industry, the pharmaceutical industry reflects
the country's business infrastructure and policies. As an indicator of science
and technology, the industry reflects the country's state of innovation in the
sciences and technologies. Given the facts, the project proponent believes that
a stronger pharmaceutical can contribute to the national competitiveness of the
country. More and better partnerships between the public and the private
sectors, between the academe and the industry, will not only strengthen the
healthcare industry, but also contribute to the overall wellbeing of Filipinos.
The purpose of this study is to assess the Philippine pharmaceutical industry
as a sectoral system of innovation. Currently, the Philippine pharmaceutical
industry is not globally competitive. There is no clear coordination within the
industry value chain. There is little innovation in this sector. The government
does not give priority to the sector. The industry is focused mainly on the
domestic market. While the industry has numerous achievements, there are
equally as many shortcomings, majority of which are systemic problems present
in the actors and institutions that make up the innovation system. Some of the
problems have existed for decades. Left unresolved, these problems have
compounded into the dilemmas we have now. This paper aims to analyze the
Philippine pharmaceutical industry as a sectoral innovation system. The
relevant actors and institutions within the system were identified. The
activities and gaps within the system were elucidated. Finally, recommendations
were offered on how to improve the industry and help it become innovative.
Combining qualitative evidence with existing policy, statistical and
technological output indicator data will hopefully provide an applicable
framework for policy makers and entrepreneurs in the Philippines to meet these
challenges of global competition and grasp the opportunities within the
industry.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.